

=> d ibib abs ind hitstr 17 1-1

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:267177 HCAPLUS  
 DOCUMENT NUMBER: 140:276210  
 TITLE: Drug delivery devices containing **neuraminidase inhibitor** and an H1 antagonist  
 INVENTOR(S): **Faour, Joaquina; Vergez, Juan A.; Ricci, Marcelo A.**  
 PATENT ASSIGNEE(S): Argent.  
 SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of WO 2004 19,917.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004062801	A1	20040401	US 2003-619720	20030715
US 2003044457	A1	20030306	US 2001-907486	20010717
US 6605302	B2	20030812		
WO 2004019917	A1	20040311	WO 2002-CR5	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002351655	A1	20040319	AU 2002-351655	20020829
PRIORITY APPLN. INFO.:			US 2001-907486	A2 20010717
			WO 2002-CR5	A2 20020829

AB The present invention provides a dual release solid dosage form containing a first composition that releases a **neuraminidase inhibitor**, such as oseltamivir, zanamivir, or peramivir, in a controlled manner and a second composition that releases an H1 antagonist in a rapid and/or immediate manner. A wide range of H1 antagonist antihistamines, especially fexofenadine and loratadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. The device is useful for the treatment of respiratory congestion and other viral infection associated symptoms. For example, osmotic device tablets containing oseltamivir phosphate and fexofenadine hydrochloride were prepared

IC ICM A61K009-22

INCL 424468000

CC 63-6 (Pharmaceuticals)

ST controlled release osmotic device **neuraminidase inhibitor** antihistamine; oseltamivir fexofenadine controlled release osmotic device

IT Antihistamines

(H1; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)

IT Monoglycerides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (acetates; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)

- IT Clays, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bentonitic; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Drug delivery systems  
 (capsules, controlled-release; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Antiviral agents  
 Dissolution  
 (controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Albumins, biological studies  
 Bentonite, biological studies  
 Carbohydrates, biological studies  
 Clays, biological studies  
 Collagens, biological studies  
 Gelatins, biological studies  
 Polyoxyalkylenes, biological studies  
 Polysaccharides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Drug delivery systems  
 (controlled-release, osmotic devices; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Drug delivery systems  
 (tablets, coated, controlled-release; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Drug delivery systems  
 (tablets, controlled-release; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT Respiratory system, disease  
 (treatment of; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT 9003-39-8D, crosslinked  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Crospovidone; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)
- IT 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 50-99-7, Glucose, biological studies 56-81-5, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 60-87-7, Prometazin 63-42-3, Lactose 69-65-8, D-Mannitol 77-92-9, Citric acid, biological studies 81-25-4, Cholic acid 97-64-3, Ethyl lactate 102-76-1, Triacetin 109-43-3, Dibutylsebacate 110-17-8, Fumaric acid, biological studies 124-07-2, Caprylic acid, biological studies 138-22-7, Butyl lactate 151-21-3, Sodium lauryl sulfate, biological studies 361-09-1, Sodium cholate 471-34-1, Calcium carbonate, biological studies 475-31-0, Glycocholic acid 623-50-7, Ethyl glycolate 1935-18-8, Palmitoyl carnitine 6915-15-7, Malic acid 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dibasic calcium phosphate 9000-30-0, Guar gum 9002-96-4, Vitamin E TPGS 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-35-7, Cellulose acetate 9004-38-0, Cellulose

acetate phthalate 9004-65-3, Hydroxypropyl methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9063-38-1, Sodium starch glycolate 9085-05-6, Cellulose acrylate 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 24937-78-8, Ethylene-vinyl acetate copolymer 25086-89-9, Vinylpyrrolidone-vinyl acetate copolymer 25322-68-3, Poly(ethylene glycol) 25322-69-4, Poly(propylene glycol) 39301-46-7, Calcium pectinate 50679-08-8, Terfenadine 58581-89-8, Azelastine 68844-77-9, Astemizole 75970-99-9, Norastemizole 79794-75-5, Loratadine 80012-43-7, Epinastine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87848-99-5, Acrivastine 90729-43-4, Ebastine 100643-71-8, Desloratadine 106392-12-5, Poloxamer 108612-45-9, Mizolastine 139110-80-8, Zanamivir 153439-40-8, Fexofenadine hydrochloride 162252-45-1, 4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid 204255-11-8, Oseltamivir phosphate 330600-85-6, Peramivir 341969-96-8 503545-51-5  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)

IT 9001-67-6, **Neuraminidase**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)

IT 9003-39-8D, crosslinked

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Crospovidone; controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)


RN 9003-39-8 HCAPLUS

CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0

CMF C6 H9 N O




IT 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 50-99-7, Glucose, biological studies 56-81-5, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 60-87-7, Prometazin 63-42-3, Lactose 69-65-8, D-Mannitol 77-92-9, Citric acid, biological studies 81-25-4, Cholic acid 97-64-3, Ethyl lactate 102-76-1, Triacetin 109-43-3, Dibutylsebacate 110-17-8, Fumaric acid, biological studies 124-07-2, Caprylic acid, biological studies 138-22-7, Butyl lactate 151-21-3, Sodium lauryl sulfate, biological studies 361-09-1, Sodium cholate 471-34-1, Calcium carbonate, biological studies 475-31-0, Glycocholic acid 623-50-7, Ethyl glycolate 1935-18-8, Palmitoyl carnitine

6915-15-7, Malic acid 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dibasic calcium phosphate 9000-30-0, Guar gum 9002-96-4, Vitamin E TPGS 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-65-3, Hydroxypropyl methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9063-38-1, Sodium starch glycolate 9085-05-6, Cellulose acrylate 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 24937-78-8, Ethylene-vinyl acetate copolymer 25086-89-9, Vinylpyrrolidone-vinyl acetate copolymer 25322-68-3, Poly(ethylene glycol) 25322-69-4, Poly(propylene glycol) 39301-46-7, Calcium pectinate 50679-08-8, Terfenadine 58581-89-8, Azelastine 68844-77-9, Astemizole 75970-99-9, Norastemizole 79794-75-5, Loratadine 80012-43-7, Epinastine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87848-99-5, Acrivastine 90729-43-4, Ebastine 100643-71-8, Desloratadine 106392-12-5, Poloxamer 108612-45-9, Mizolastine 139110-80-8, Zanamivir 153439-40-8, Fexofenadine hydrochloride 162252-45-1, 4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid 204255-11-8, Oseltamivir phosphate 330600-85-6, Peramivir 341969-96-8 503545-51-5  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (controlled-release drug delivery device containing **neuraminidase inhibitor** and H1 antagonist)

RN 50-70-4 HCAPLUS

CN D-Glucitol (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-81-7 HCAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 50-99-7 HCAPLUS

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 56-81-5 HCAPLUS  
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)




RN 57-50-1 HCAPLUS  
CN  $\alpha$ -D-Glucopyranoside,  $\beta$ -D-fructofuranosyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-55-6 HCAPLUS  
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)




RN 60-87-7 HCAPLUS  
CN 10H-Phenothiazine-10-ethanamine, N,N, $\alpha$ -trimethyl- (9CI) (CA INDEX NAME)



RN 63-42-3 HCAPLUS

CN D-Glucose, 4-O-β-D-galactopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 69-65-8 HCAPLUS


CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77-92-9 HCAPLUS


CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 81-25-4 HCAPLUS


CN Cholan-24-oic acid, 3,7,12-trihydroxy-, (3α,5β,7α,12.αph a.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 97-64-3 HCAPLUS

CN Propanoic acid, 2-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 102-76-1 HCAPLUS

CN 1,2,3-Propanetriol, triacetate (9CI) (CA INDEX NAME)



RN 109-43-3 HCAPLUS


CN Decanedioic acid, dibutyl ester (9CI) (CA INDEX NAME)



RN 110-17-8 HCAPLUS


CN 2-Butenedioic acid (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 124-07-2 HCAPLUS

CN Octanoic acid (8CI, 9CI) (CA INDEX NAME)




RN 138-22-7 HCAPLUS

CN Propanoic acid, 2-hydroxy-, butyl ester (9CI) (CA INDEX NAME)



RN 151-21-3 HCAPLUS

CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)




● Na

RN 361-09-1 HCAPLUS

CN Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3 $\alpha$ ,5 $\beta$ ,7 $\alpha$ ,12 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 471-34-1 HCAPLUS

CN Carbonic acid calcium salt (1:1) (8CI, 9CI) (CA INDEX NAME)




● Ca

RN 475-31-0 HCAPLUS

CN Glycine, N-[(3 $\alpha$ ,5 $\beta$ ,7 $\alpha$ ,12 $\alpha$ )-3,7,12-trihydroxy-24-oxocholan-24-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 623-50-7 HCAPLUS

CN Acetic acid, hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 1935-18-8 HCAPLUS

CN 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-[(1-oxohexadecyl)oxy]-, inner salt (9CI) (CA INDEX NAME)



RN 6915-15-7 HCAPLUS

CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)




RN 7647-14-5 HCAPLUS

CN Sodium chloride (NaCl) (9CI) (CA INDEX NAME)

Cl<sup>-</sup> Na

RN 7757-93-9 HCAPLUS

CN Phosphoric acid, calcium salt (1:1) (8CI, 9CI) (CA INDEX NAME)




● Ca

RN 9000-30-0 HCAPLUS  
 CN Guar gum (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9002-96-4 HCAPLUS  
 CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -[4-[[ (2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]- $\omega$ -hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 9003-39-8 HCAPLUS  
 CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0  
 CMF C6 H9 N O



RN 9004-32-4 HCAPLUS  
 CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 79-14-1  
CMF C2 H4 O3



RN 9004-34-6 HCAPLUS  
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9004-35-7 HCAPLUS  
CN Cellulose, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 9004-38-0 HCAPLUS  
CN Cellulose, acetate hydrogen 1,2-benzenedicarboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2

CRN 88-99-3  
CMF C8 H6 O4



CM 3

CRN 64-19-7  
CMF C2 H4 O2



RN 9004-65-3 HCAPLUS  
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


CM 2

CRN 67-56-1  
CMF C H4 O



CM 3

CRN 57-55-6  
CMF C3 H8 O2



RN 9005-25-8 HCAPLUS  
CN Starch (8CI, 9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9005-32-7 HCAPLUS

CN Alginic acid (8CI, 9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9063-38-1 HCAPLUS

CN Starch, carboxymethyl ether, sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 9005-25-8

CMF Unspecified


CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 79-14-1

CMF C2 H4 O3



RN 9085-05-6 HCAPLUS

CN Cellulose, 2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2


CRN 79-10-7

CMF C3 H4 O2




RN 13463-67-7 HCAPLUS

CN Titanium oxide (TiO<sub>2</sub>) (8CI, 9CI) (CA INDEX NAME)



RN 14807-96-6 HCAPLUS

CN Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>) (9CI) (CA INDEX NAME)




● 3/4 Mg

RN 24937-78-8 HCAPLUS  
CN Acetic acid ethenyl ester, polymer with ethene (9CI) (CA INDEX NAME)

CM 1

CRN 108-05-4

CMF C4 H6 O2



CM 2

CRN 74-85-1

CMF C2 H4




RN 25086-89-9 HCAPLUS  
CN Acetic acid ethenyl ester, polymer with 1-ethenyl-2-pyrrolidinone (9CI)  
(CA INDEX NAME)

CM 1

CRN 108-05-4


CMF C4 H6 O2



CM 2


CRN 88-12-0

CMF C6 H9 N O




RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -hydro- $\omega$ -hydroxy- (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS

CN Poly[oxy(methyl-1,2-ethanediyl)],  $\alpha$ -hydro- $\omega$ -hydroxy- (9CI)  
(CA INDEX NAME)




RN 39301-46-7 HCAPLUS

CN Pectin, calcium salt (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


RN 50679-08-8 HCAPLUS

CN 1-Piperidinebutanol,  $\alpha$ -[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- (9CI) (CA INDEX NAME)




RN 58581-89-8 HCAPLUS


CN 1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)




RN 68844-77-9 HCAPLUS  
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 75970-99-9 HCAPLUS  
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 79794-75-5 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)




RN 80012-43-7 HCAPLUS  
 CN 1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- (9CI) (CA INDEX NAME)






RN 83799-24-0 HCAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

RN 83881-51-0 HCAPLUS


CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 87848-99-5 HCAPLUS


CN 2-Propenoic acid, 3-[6-[(1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 90729-43-4 HCAPLUS

CN 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 100643-71-8 HCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)




RN 106392-12-5 HCAPLUS

CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9

CMF C3 H6 O



CM 2


CRN 75-21-8

CMF C2 H4 O



RN 108612-45-9 HCAPLUS


CN 4(1H)-Pyrimidinone, 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- (9CI) (CA INDEX NAME)



RN 139110-80-8 HCAPLUS


CN D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-  
[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



RN 153439-40-8 HCAPLUS


CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-  
piperidiny]butyl]- $\alpha,\alpha$ -dimethyl-, hydrochloride (9CI) (CA  
INDEX NAME)



● HCl

RN 162252-45-1 HCAPLUS

CN Benzoic acid, 4-(acetylamino)-3-hydroxy-5-nitro- (9CI) (CA INDEX NAME)




RN 204255-11-8 HCAPLUS  
 CN 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 196618-13-0  
 CMF C16 H28 N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 7664-38-2  
 CMF H3 O4 P



RN 330600-85-6 HCAPLUS  
 CN Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 341969-96-8 HCAPLUS  
 CN 3-Pyrrolidinecarboxylic acid, 4-amino-1-[[ethyl(1-methylethyl)amino]carbonyl]-5-[[[(trifluoroacetyl)amino]methyl]-,

(3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503545-51-5 HCAPLUS


CN D-Glucitol, 2-hydroxypropanoate (9CI) (CA INDEX NAME)

CM 1

CRN 50-70-4

CMF C6 H14 O6


Absolute stereochemistry.



CM 2

CRN 50-21-5

CMF C3 H6 O3



IT 9001-67-6, Neuraminidase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**inhibitors**; controlled-release drug delivery device containing  
**neuraminidase inhibitor** and H1 antagonist)

RN 9001-67-6 HCAPLUS

CN Neuraminidase (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> d his

(FILE 'HOME' ENTERED AT 14:26:22 ON 08 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 14:26:30 ON 08 SEP 2006

L1           E FAOUR JOAQUINA/AU  
          32 S E2-3  
          E VERGEZ JUAN A/AU  
L2           18 S E3  
          E RICCI MARCELO A/AU  
L3           15 S E2-3  
L4           7 S L1 AND L2 AND L3  
L5           1 S L4 AND ?NEURAMINIDASE?(W)?INHIBIT?  
          SELECT RN L5 1

FILE 'REGISTRY' ENTERED AT 14:27:29 ON 08 SEP 2006

L6           66 S E1-66

FILE 'HCAPLUS' ENTERED AT 14:27:59 ON 08 SEP 2006

L7           1 S L5 AND L6  
L8           ANALYZE L7 1 CT :       14 TERMS

=>